Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients

NCT02297698 is registered in ClinicalTrials.gov with Cancer Insight, LLC as lead sponsor.

NCT NCT02297698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02297698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Lead sponsor
Cancer Insight, LLC
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2014
Completion date
December 31, 2021
Enrollment
100 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer